234 related articles for article (PubMed ID: 23643389)
1. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
[TBL] [Abstract][Full Text] [Related]
2. Novel all-hydrocarbon stapled p110α[E545K] peptides as blockers of the oncogenic p110α[E545K]-IRS1 interaction.
Hu X; He Y; Wu L; Hao Y; Wang Z; Zheng W
Bioorg Med Chem Lett; 2017 Dec; 27(24):5446-5449. PubMed ID: 29138025
[TBL] [Abstract][Full Text] [Related]
3. Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.
Hao Y; Zhao S; Wang Z
Toxicol Pathol; 2014 Jan; 42(1):140-7. PubMed ID: 24178578
[TBL] [Abstract][Full Text] [Related]
4. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
5. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
[TBL] [Abstract][Full Text] [Related]
6. Human tumor mutants in the p110alpha subunit of PI3K.
Liu Z; Roberts TM
Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
9. p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.
Chaudhari A; Krumlinde D; Lundqvist A; Akyürek LM; Bandaru S; Skålén K; Ståhlman M; Borén J; Wettergren Y; Ejeskär K; Rotter Sopasakis V
Mol Cell Biol; 2015 Oct; 35(19):3258-73. PubMed ID: 26169833
[TBL] [Abstract][Full Text] [Related]
10. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
Blair BG; Wu X; Zahari MS; Mohseni M; Cidado J; Wong HY; Beaver JA; Cochran RL; Zabransky DJ; Croessmann S; Chu D; Toro PV; Cravero K; Pandey A; Park BH
Proteomics; 2015 Jan; 15(2-3):318-26. PubMed ID: 25367220
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
[TBL] [Abstract][Full Text] [Related]
12. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
Zhao L; Vogt PK
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322
[TBL] [Abstract][Full Text] [Related]
13. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
Bader AG; Kang S; Vogt PK
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
[TBL] [Abstract][Full Text] [Related]
15. Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Ross RL; Burns JE; Taylor CF; Mellor P; Anderson DH; Knowles MA
PLoS One; 2013; 8(12):e84411. PubMed ID: 24367658
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
[TBL] [Abstract][Full Text] [Related]
17. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Huang CH; Mandelker D; Gabelli SB; Amzel LM
Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Lipid Alterations by Oncogenic
Jung JH; Yang DQ; Song H; Wang X; Wu X; Kim KP; Pandey A; Byeon SK
OMICS; 2023 Jul; 27(7):327-335. PubMed ID: 37463468
[TBL] [Abstract][Full Text] [Related]
19. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Dbouk HA; Pang H; Fiser A; Backer JM
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
[TBL] [Abstract][Full Text] [Related]
20. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z
Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
